Prevalence of Marijuana Use Disorders in the United States Between 2001-2002 and 2012-2013

JAMA Psychiatry, Journal Year: 2015, Volume and Issue: 72(12), P. 1235 - 1235

Published: Oct. 21, 2015

Laws and attitudes toward marijuana in the United States are becoming more permissive but little is known about whether prevalence rates of use disorders have changed 21st century.To present nationally representative information on past-year use, disorder, disorder among users US adult general population this has between 2001-2002 2012-2013.Face-to-face interviews conducted surveys 2 samples adults: National Epidemiologic Survey Alcohol Related Conditions (data collected April 2001-April 2002; N = 43,093) Conditions-III 2012-June 2013; 36,309). Data were analyzed March through May 2015.Past-year DSM-IV (abuse or dependence).The was 4.1% (SE, 0.15) 9.5% 0.27) 2012-2013, a significant increase (P < .05). Significant increases also found across demographic subgroups (sex, age, race/ethnicity, education, marital status, income, urban/rural, region). The 1.5% (0.08) 2.9% 0.13) 2012-2013 With few exceptions, statistically .05) subgroups. However, decreased significantly from (35.6%; SE, 1.37) to (30.6%; 1.04).The than doubled there large during that time. While not all experience problems, nearly 3 10 manifested 2012-2013. Because risk for did users, owing an population. Given changing laws marijuana, balanced presentation likelihood adverse consequences policy makers, professionals, public needed.

Language: Английский

---

Prevalence and Correlates of DSM-5 Cannabis Use Disorder, 2012-2013: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions–III

American Journal of Psychiatry, Journal Year: 2016, Volume and Issue: 173(6), P. 588 - 599

Published: March 4, 2016

Attitudes toward marijuana are changing, the prevalence of DSM-IV cannabis use disorder has increased, and DSM-5 modified criteria. Therefore, updated information is needed on prevalence, demographic characteristics, psychiatric comorbidity, disability, treatment for disorder.

Language: Английский

---

US Adult Illicit Cannabis Use, Cannabis Use Disorder, and Medical Marijuana Laws

JAMA Psychiatry, Journal Year: 2017, Volume and Issue: 74(6), P. 579 - 579

Published: April 26, 2017

Over the last 25 years, illicit cannabis use and disorders have increased among US adults, 28 states passed medical marijuana laws (MML). Little is known about MML adult or considered over time.

Language: Английский

---

Keep off the grass? Cannabis, cognition and addiction

Nature reviews. Neuroscience, Journal Year: 2016, Volume and Issue: 17(5), P. 293 - 306

Published: April 7, 2016

Language: Английский

---

Cannabis use and cannabis use disorder

Nature Reviews Disease Primers, Journal Year: 2021, Volume and Issue: 7(1)

Published: Feb. 25, 2021

Language: Английский

---

Public health implications of legalising the production and sale of cannabis for medicinal and recreational use

The Lancet, Journal Year: 2019, Volume and Issue: 394(10208), P. 1580 - 1590

Published: Oct. 1, 2019

Language: Английский

---

Psychosocial interventions for cannabis use disorder

Cochrane library, Journal Year: 2016, Volume and Issue: unknown

Published: May 5, 2016

Language: Английский

---

Estimating treatment coverage for people with substance use disorders: an analysis of data from the World Mental Health Surveys

World Psychiatry, Journal Year: 2017, Volume and Issue: 16(3), P. 299 - 307

Published: Sept. 21, 2017

Substance use is a major cause of disability globally. This has been recognized in the recent United Nations Sustainable Development Goals (SDGs), which treatment coverage for substance disorders identified as one indicators. There have no estimates this cross‐nationally, making it difficult to know what baseline that SDG target. Here we report data from World Health Organization (WHO)'s Mental Surveys (WMHS), based on representative community household surveys 26 countries. We assessed 12‐month prevalence (alcohol or drug abuse/dependence); proportion people with these who were aware they needed and wished receive care; those seeking care received it; such met minimal standards quality (“minimally adequate treatment”). Among 70,880 participants, 2.6% criteria disorders; was higher upper‐middle income (3.3%) than high‐income (2.6%) low/lower‐middle (2.0%) Overall, 39.1% need; recognition more common (43.1%) (35.6%) (31.5%) need, 61.3% made at least visit service provider, 29.5% latter minimally exposure (35.3% high, 20.3% upper‐middle, 8.6% countries). only 7.1% past‐year treatment: 10.3% high income, 4.3% 1.0% These suggest small minority even treatment. At three barriers are involved: awareness/perceived accessing once need recognized, compliance (on part both provider client) obtain Various factors likely be involved each barriers, all addressed improve disorders. provide global monitoring progress an indicator within SDGs.

Language: Английский

---

Alpha₂delta ligands, gabapentin, pregabalin and mirogabalin: a review of their clinical pharmacology and therapeutic use

Expert Review of Neurotherapeutics, Journal Year: 2016, Volume and Issue: 16(11), P. 1263 - 1277

Published: June 27, 2016

Introduction: The first two alpha2delta ligands – gabapentin (GBP) and pregabalin (PGB) were initially synthesized as antiepileptics; however, they later also found to be useful for the treatment of additional conditions.Areas covered: Relevant publications describing potential underlying mechanisms, clinical pharmacokinetics/pharmacokinetics, efficacy safety these drugs in various disease conditions searched PubMed Scopus included this review.Expert commentary: GBP PGB are effective neuropathic pain, fibromyalgia epilepsy; addition, may reduction postoperative pain. is generalized anxiety disorder restless legs syndrome. considered a option pain associated with Guillain-Barré Syndrome phantom limb management uremic pruritus. Mirogabalin (MGB), recently developed, being investigated peripheral fibromyalgia, showing promising results patients diabetic neuropathy. Their most frequent adverse reactions neuropsychiatric nature include fatigue, dizziness, sedation, somnolence, ataxia; edema weight gain frequently described. Pharmacokinetic interactions scarce; pharmacodynamic have been described association CNS-depressant effects.

Language: Английский

---

Treatment of Cannabis Use Disorder: Current Science and Future Outlook

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, Journal Year: 2016, Volume and Issue: 36(5), P. 511 - 535

Published: March 30, 2016

Cannabis is the most commonly used illicit substance in United States. Rates of cannabis use and disorder (CUD) have increased past decade, paralleling changes legal political climate favoring legalization. Almost 20 million people 12 years or older report past‐month use, 8 daily near‐daily use. Concurrently, perception that poses a significant risk negative consequences has decreased. Contrary to this perception, heavy associated with cognitive impairment, for psychotic disorders other mental health problems, lower education attainment, unemployment. Clinical trials various treatments CUD likewise increased, focusing primarily on psychotherapy treatments, specifically motivational enhancement therapy, behavioral contingency management. Their findings suggest combination these three modalities produces best abstinence outcomes, although rates remain modest decline after treatment. More recently, pharmacotherapy been conducted as adjunctive interventions psychosocial N ‐acetylcysteine gabapentin are two promising medications, no pharmacologic treatment emerged clearly efficacious. In review, we provide detailed summary clinical evaluated treating discuss emerging areas research cannabis‐specific barriers

Language: Английский

---